Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25615634 | 1.00 | USP30 (0.47) | USP30DDB1CRBNGPR119FFAR1 | |
| SCHEMBL320828 | 0.89 | USP30 (0.52) | USP30DDB1CRBNGPR119FFAR1 | |
| SCHEMBL25238268 | 0.86 | USP30 (0.49) | USP30DDB1CRBNGPR119FFAR1 | |
| SCHEMBL2423601 | 0.85 | USP30 (0.55) | USP30DDB1CRBNGPR119FFAR1 | |
| SCHEMBL2422527 | 0.85 | USP30 (0.55) | USP30DDB1CRBNGPR119FFAR1 | |
| SCHEMBL2422530 | 0.85 | USP30 (0.55) | USP30DDB1CRBNGPR119FFAR1 | |
| SCHEMBL25209448 | 0.85 | USP30 (0.46) | USP30GPR119FFAR1NPBWR1MCHR1 | |
| SCHEMBL25615939 | 0.85 | USP30 (0.46) | USP30GPR119FFAR1NPBWR1MCHR1 | |
| SCHEMBL21456533 | 0.84 | USP30 (0.43) | USP30GPR119FFAR1NPBWR1MCHR1 | |
| SCHEMBL17122082 | 0.84 | USP30 (0.51) | USP30DDB1CRBNGPR119FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064945-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4436965-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064945-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | USP30 251/4885DDB1 73/4885CRBN 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.